论文部分内容阅读
目的探讨CD133和CD45在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法采用免疫组织化学SABC法检测65例NSCLC组织中CD133和CD45的表达,分析两者与肿瘤大小、组织学类型、TNM分期、组织分化程度及淋巴结转移之间的关系。结果 CD133和CD45在NSCLC组织中的阳性表达率分别为69.2%(45/65)和41.5%(27/65)。CD133的表达与肿瘤大小、组织学类型、TNM分期、组织分化程度无关(P>0.05);有淋巴结转移者的CD133阳性表达率为82.5%(33/40),高于无淋巴结转移者的48.0%(12/25),差异有统计学意义(χ2=7.053,P=0.008)。CD45的表达与肿瘤大小、组织学类型、TNM分期和有无淋巴结转移无关(P>0.05);高、中分化者的CD45阳性表达率为53.7%(22/41),高于低分化者的20.8%(5/24),差异有统计学意义(χ2=5.433,P=0.019)。结论 CD133+/CD45-可能是NSLLC肿瘤干细胞的部分表型特征。
Objective To investigate the expression and clinical significance of CD133 and CD45 in non-small cell lung cancer (NSCLC). Methods The expressions of CD133 and CD45 in 65 cases of NSCLC were detected by immunohistochemical SABC method. The relationship between them and tumor size, histological type, TNM stage, histological differentiation and lymph node metastasis were analyzed. Results The positive rates of CD133 and CD45 in NSCLC tissues were 69.2% (45/65) and 41.5% (27/65), respectively. The expression of CD133 was not associated with tumor size, histological type, TNM stage and histological differentiation (P> 0.05). The positive rate of CD133 in patients with lymph node metastasis was 82.5% (33/40), which was higher than that in patients without lymph node metastasis % (12/25), the difference was statistically significant (χ2 = 7.053, P = 0.008). The expression of CD45 was not associated with tumor size, histological type, TNM stage and lymph node metastasis (P> 0.05). The positive rate of CD45 in high and moderately differentiated patients was 53.7% (22/41), which was higher than that in poorly differentiated 20.8% (5/24), the difference was statistically significant (χ2 = 5.433, P = 0.019). Conclusion CD133 + / CD45- may be a partial phenotypic characteristic of NSLLC tumor stem cells.